Spurious Drug Factory Busted In Gandhinagar

Ahmedabad: The Gujarat Food and Drug Administration (FDCA) raided a factory operating illegally within the Gujarat Industrial Development Corporation (GIDC) estate in Gandhinagar. The unit, owned by Bhavin Patel, was making medicines with a licence. The authorities suspect the factory was supplying “substandard and potentially harmful drugs across the state”, a press release from Gujarat FDCA said.

Gujarat FDCA commissioner H G Koshia said the raid unearthed a web of irregularities. Patel allegedly used fake production licences and did not have a qualified technician on the staff. Investigators suspect tablet fillers such as dibasic calcium phosphate (DCP) or starch were being used with no or improper active pharmaceutical ingredients (APIs) in medication that was sold as azithromycin, paracetamol, methylcobalamin (a vitamin B12 drug), pregabalin (analgesic) and thiocolchicoside (rheumatism drug).

“We found that they had replaced methylcobalamin, pregabalin and thiocolchicoside with DCP, starch or cheaper APIs and sold these spurious medicines. We have taken samples and are filing a case against them,” Koshia said.

Patel allegedly obtained fake production licences and GSTIN/UIN to set up the factory. “He procured the machinery to make tablets and capsules and had even secured a bank loan. Dummy pellets, empty capsule shells, omeprazole capsules, omeprazole pellets and maize starch powder were found at the factory,” Koshia added. The raid led to seizures of machinery, packaging material and counterfeit APIs, worth about Rs 4 crore.

Raw materials and finished products valued at Rs 43 lakh were also seized, the Gujarat FDCA statement said.

Related Posts

PGIMS recalls drug amid probe into deaths

The PGIMS authorities have directed all departments to immediately stop using a specific batch of injectable Propofol, an anaesthetic drug, and return the available stock to the central store. The…

NPPA list brings little relief: No price cut for 25% cancer drugs

Mumbai: Nearly one in four cancer drug packs in a revised price list issued by the National Pharmaceutical Pricing Authority (NPPA) has seen no reduction in maximum retail price (MRP),…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

PGIMS recalls drug amid probe into deaths

PGIMS recalls drug amid probe into deaths

NPPA list brings little relief: No price cut for 25% cancer drugs

NPPA list brings little relief: No price cut for 25% cancer drugs

Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

For Aakash Healthcare, Community People are Apples of its Eyes

For Aakash Healthcare, Community People are Apples of its Eyes

Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

Yashoda Medicity: Baby takes a Giant Step in just One Year

Yashoda Medicity: Baby takes a Giant Step in just One Year